Trial Profile

A Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab With or Without Maintenance Olaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 09 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Olaparib (Primary) ; Pembrolizumab (Primary) ; Carboplatin; Paclitaxel
Indications Non-small cell lung cancer; Squamous cell cancer
Focus Registrational; Therapeutic Use
Acronyms KEYLYNK008; MK-7339-008; MK-7339-008KEYLYNK-008
Sponsors Merck Sharp & Dohme Corp.

16 Oct 2025 Planned End Date changed from 31 Dec 2025 to 30 Jan 2026.
16 Jan 2025 Planned End Date changed from 12 Mar 2025 to 31 Dec 2025.
06 Nov 2024 The protocol has been amended to change in the study time frame for its both primary endpoints.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com